Compare Fox Corp Class B (FOX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs IDEXX Laboratories, Inc. — how do they compare? Fox Corp Class B trades at $55.26 (market cap $24.58B), while IDEXX Laboratories, Inc. trades at $572.77 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Fox Corp Class B pays a 1.05% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| FOX | IDXX | |
|---|---|---|
Market Cap | $24.58B | $46.22B |
Sector | Media | Health |
52-Week High | $67.76 | $766.68 |
52-Week Low | $44.39 | $526.44 |
Enterprise Value | $27.94B | $47.12B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.32, down 1.79% on the day, with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.79 exceeding the $1.44 estimate, and revenue growth to $16.30 billion in 2025. A dividend of $0.29 is scheduled for September 2026, reflecting financial health. Analyst sentiment is mixed but leans positive, with 42.86% recommending buy.
The outlook for FOX is favorable, driven by digital growth and advertising momentum, though risks include competitive pressures and potential economic volatility. The stock's valuation metrics, including a P/E of 14.41, suggest reasonable pricing relative to earnings, supporting a cautious optimism for investors seeking exposure to media and entertainment sectors.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
